Results 141 to 150 of about 5,427 (186)

Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF^V600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison. [PDF]

ESMO Open
Planchard D, Mazières J, Grouin JM, Le Reun C, Luttenauer H, Boussahoua M, Macabeo B.   +6 more
europepmc   +1 more source

COLUMBUS part 1-7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma. [PDF]

Future Oncol
Schadendorf D.
europepmc   +1 more source

Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials. [PDF]

BMJ Open
Peinemann F, Baradaran S, Arnolds KB, Hoemberg M.   +3 more
europepmc   +1 more source

Ophthalmic Toxicities in BEACON Triplet Therapy for BRAF V600E-Mutant Colorectal Cancer: A Case Series. [PDF]

J Anus Rectum Colon
Nakamura H, Suzumura K, Oiwa K, Tsuchiya T, Nishimae K, Tanaka M, Terasaki M, Okamoto Y.   +7 more
europepmc   +1 more source

Targeted therapies and PARPi therapy response following ICI therapy failure in advanced melanoma: a case series. [PDF]

Melanoma Manag
Nassief G, Morecroft R, Phillipps J, Chen D, Ansstas G.   +4 more
europepmc   +1 more source

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer. [PDF]

J Clin Oncol
Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ.   +20 more
europepmc   +1 more source

Surrogate to predict overall survival in patients with <i>BRAF</i> V600E-mutant colorectal cancer treated with BRAF inhibitor combinations. [PDF]

ESMO Gastrointest Oncol
Ros J, Navarro V, Villacampa G, Baraibar I, Salvà F, Rodriguez M, Vaghi C, Garcia A, Alcaraz A, Tabernero J, Élez E, Dienstmann R.   +11 more
europepmc   +1 more source

POLARIS: encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis. [PDF]

Future Oncol
Menzies AM, Davies MA.
europepmc   +1 more source

Personalized therapies in advanced BRAFV600-mutated melanoma: review based on 3 case reports of the REMINISCENCE project. [PDF]

Melanoma Manag
Gebhardt C, Debus D, Rohrer P, Kähler KC, Koch L, Terheyden P, Nguyen VA.   +6 more
europepmc   +1 more source

A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis. [PDF]

Future Oncol
Menzies AM, Long GV, Kohn A, Tawbi H, Webe J, Flaherty K, McArthur GA, Ascierto PA, Pfluger Y, Lewis K, Tsai KK, Hamid O, Prenen H, Fein L, Wang E, Guenzel C, Zhang F, Kleh JF, di Pietro A, Davies MA.   +19 more
europepmc   +1 more source